Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Blood (2024) 144 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2024-207175

Published: 2024

Journal Articles

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Massimo Breccia, Alessandra Iurlo, Fabrizio Pane, Anna Rita Scortechini, Immacolata Attolico, Marco Santoro, Marco Cerrano, Francesca Lunghi, Alessandro Maggi, Nicola Di Renzo, Valeria Sargentini, Alfonso Piciocchi, Claudia Tringali, Alessandra Malato

Blood (2024) 144 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2024-200389

Published: 2024

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Real-Life Data of Bosutinib Treatment for Chronic Myeloid Leukemia: The Multi-Center Experience of the Gruppo Di Miglioramento Sicilia-Calabria

Marco Santoro, Sabina Russo, Iolanda Donatella Vincelli, Emilia Cotzia, Stefana Impera, Vincenzo Leone, Luciano Levato, Francesco Mendicino, Alessandra Malato, Mineo Giuseppe, Laura Nocilli, Ferdinando Porretto, Bruno Martino, Sergio Siragusa, Carmela Anna Maria Tomaselli

Blood (2023) 142 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2023-185120

Published: 2023

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Blood (2022) 140 (Supplement 1): 9685–9687.

https://doi.org/10.1182/blood-2022-156371

Published: 2022

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Massimo Breccia, Luigia Luciano, Mario Annunziata, Imma Attolico, Alessandra Malato, Elisabetta Abruzzese, Massimiliano Bonifacio, Anna Rita Scortechini, Nicola Cascavilla, Nicola Di Renzo, Stefana Impera, Monia Lunghi, Marco Santoro, Fausto Castagnetti, Alessandro Maggi, Valeria Sargentini, Alfonso Piciocchi, Claudia Galimberti, Alessandra Iurlo

Blood (2021) 138 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2021-146139

Published: 2021

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

Journal Articles

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141077

Published: 2020

Journal Articles

Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139826

Published: 2020

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)

Massimo Breccia, MD, Paola Guglielmelli, MD PhD, Alessandra Malato, MD, Francesco Mendicino, MD, Giuseppe A. Palumbo, MD, Carmine Selleri, MD, Daniela Cilloni, MD PhD, Patrizio Mazza, MD, Sergio Siragusa, MD Professor, Elisabetta Abruzzese, Roberto Latagliata, Monica Crugnola, MD, Domenico Pastore, MD PhD, Giorgia Micucci, MD, Giulia Benevolo, MD, Mara Morelli, MD, Francesca Palandri, PhD MD, Francesco Passamonti

Blood (2018) 132 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2018-99-110198

Published: 2018

Journal Articles

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Luigia Luciano, MD, Giorgina Specchia, MD, Bruno Martino, Vincenzo Accurso, MD, Marco Santoro, MD, Alessandra Malato, MD, Nicola Sgherza, Michele Pizzuti, MD, Fabio Stagno, MD PhD, Pellegrino Musto, MD, Attilio Guarini, MD, Fiorenza De Gregorio, MD, Santina Basile, MD, Fabrizio Pane, MD

Blood (2017) 130 (Supplement 1): 2905.

https://doi.org/10.1182/blood.V130.Suppl_1.2905.2905

Published: 2017

Journal Articles

First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study

Blood (2017) 130 (Supplement 1): 1604.

https://doi.org/10.1182/blood.V130.Suppl_1.1604.1604

Published: 2017

Journal Articles

Interventional Strategies to Contain Colonization and Infections Caused By Carbapenemase Producing Klebsiella Pneumonia in Haematological Malignancies

Alessandra Malato, MD PhD, Francesco Acquaviva, Rosaria Felice, MD, Silvana Magrin, MD, Maria Grazia Donà, Rosanna Scimè, MD, Stefania Tringali, MD, Baldi maria Teresa, MD, Francesco Fabbiano, MD

Blood (2014) 124 (21): 2647.

https://doi.org/10.1182/blood.V124.21.2647.2647

Published: 2014

Journal Articles

Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up

Walter Ageno, MD, Nicoletta Riva, Sam Schulman, MD PhD, Jan Beyer-Westendorf, MD, Soo-Mee Bang, Marco Senzolo, Elvira Grandone, Giovanni Barillari, Matteo Di Minno, Rita Duce, Alessandra Malato, Rita Santoro, Daniela Poli, Peter Verhamme, MD PhD, Ida Martinelli, Pieter W. Kamphuisen, MD PhD, Francesco Dentali, MD

Blood (2014) 124 (21): 592.

https://doi.org/10.1182/blood.V124.21.592.592

Published: 2014

NARROW

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Real-Life Data of Bosutinib Treatment for Chronic Myeloid Leukemia: The Multi-Center Experience of the Gruppo Di Miglioramento Sicilia-Calabria

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study

Interventional Strategies to Contain Colonization and Infections Caused By Carbapenemase Producing Klebsiella Pneumonia in Haematological Malignancies

Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only